Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine · generic available

Ergotamine tartrate

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

What is Ergotamine tartrate used for?
The FDA-approved label (Ergomar Sublingual, Pangea Pharmaceuticals LLC, February 25, 2025) says: “Ergomar ® is indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called "histaminic cephalalgia".” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Ergotamine tartrate have a boxed warning?
Yes. The FDA label for Ergomar Sublingual has a boxed warning, the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
Is there a shortage of Ergotamine tartrate?
No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
Has Ergotamine tartrate been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Ergotamine tartrate?
1 company lists prescription products of Ergotamine tartrate in the FDA NDC Directory, including Pangea Pharmaceuticals, LLC.

What Ergotamine tartrate is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

Ergomar ® is indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called "histaminic cephalalgia".

— FDA label: Ergomar Sublingual, Pangea Pharmaceuticals LLC, effective February 25, 2025. Read the full label on DailyMed →

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

This label has a boxed warning. Read it on the full label →

Forms and how it is given

Dosage formsTablet
RouteOral
Prescription products1 in the FDA NDC Directory
Brand namesErgomar Sublingual

What pharmacies pay (NADAC)

The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.

This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.

NADAC per unit for Ergotamine tartrate, by strength and form
Strength and formGeneric or brandPharmacies pay
ergotamine tartrate 2 mg
tablet
Brand: Ergomar Sublingual $43.71 per tablet

NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.

Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • ANDA: Abbreviated New Drug Application: how a generic version is approved.

Generic approvals (1)

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)1293862, 1293864
SPL set ID of the quoted labela9582fdb-7ddd-4f69-aa7a-66247cdb8c92
FDA labels (SPL)1
FDA applications1 ANDA
Active ingredients (FDA)ERGOTAMINE

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Ergomar Sublingual, Pangea Pharmaceuticals LLC, effective February 25, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers